Management and outcomes after neoadjuvant treatment for locally advanced breast cancer in older versus younger women

Caroline Wium Hansen, Marianne Vogsen*, Annette Raskov Kodahl

*Corresponding author for this work

Research output: Contribution to journalJournal articleResearchpeer-review

5 Downloads (Pure)


Aim: This study examined treatment and survival among women with locally advanced breast cancer (LABC) through comparative analyses of women ≥70 years and those <70 years. The primary endpoint was surgery with curative intention following neoadjuvant therapy. Secondary endpoints were 3-year disease free survival (DFS), overall survival (OS), response rates, and adherence to treatment guidelines. Methods: Patients diagnosed and treated for LABC between 2010 and 2019 at Odense University Hospital, Denmark, were eligible. Surgical information was dichotomized into surgery and no surgery for patients ≥70 years and <70 years, and treatment response was extracted from scan and pathology reports. Adherence to treatment guidelines was registered for the initiated neoadjuvant treatment, and 3-year OS and DFS were estimated using Kaplan–Meier and Log-rank-test. Results: Of 210 women, 57/102 (55.9%) of those ≥70 years received surgery with curative intent compared with 103/108 (95.4%) of those <70 years. The main reason for omitting surgery was the patient’s request. Fewer women ≥70 years received neoadjuvant therapy according to guidelines compared with their younger counterparts (63.7% versus 98.1%, p < 0.001), but treatment response for women who underwent surgery was similar in both groups. A non-significant difference in 3-year DFS and OS was observed between the groups. Three-year DFS was 80.5% and 73.3%, whereas 3-year OS was 89.6% and 88.7% for patients ≥70 years and <70 years, respectively. Conclusion: Among women with LABC, women ≥70 years were less likely to receive neoadjuvant therapy according to guidelines. Only half of the patients ≥70 years reached the goal of surgery with curative intent, with no difference in 3-year OS and DFS between age groups.

Original languageEnglish
JournalActa Oncologica
Issue number11
Pages (from-to)1362-1368
Publication statusPublished - Nov 2022


  • Locally advanced breast cancer
  • neoadjuvant treatment
  • older women
  • survival
  • younger women
  • Disease-Free Survival
  • Breast Neoplasms/surgery
  • Humans
  • Female
  • Neoadjuvant Therapy
  • Aged
  • Retrospective Studies


Dive into the research topics of 'Management and outcomes after neoadjuvant treatment for locally advanced breast cancer in older versus younger women'. Together they form a unique fingerprint.

Cite this